RxDoctor Payments Data

Rebekah Baltz, MD

Dermatology · Fayetteville, ARNPI 1992119770

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.7% of the total across 391 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,084, 4.6 times the $450 reported in 2019.

$7,855in general payments, 2019–2025

Across 391 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$1K
  • Johnson & Johnson$1K
  • Lilly USA, LLC$883
  • Novartis$744
  • Sanofi$632
  • plus $2K from 22 others
$108,311in research payments, 2019–2025

Across 70 payments — averaging $1547.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$72K
  • Incyte Corporation$37K

What the payments were for

  • Food & beverage$7,28293%
  • Education$5737%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,855 in reported general payments places this provider in the 75th percentile of 75 dermatology providers in Arkansas.

See all dermatology providers in Arkansas

Medicare billing

Part B allowed, 2024
$175,750
Medicare patients
515
Services billed
3,721

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Taltz SyringeIxekizumab13$88,462
Dupixent PenDupilumab17$64,100
Clobetasol Propionate70$3,754
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc44$1,415
Tretinoin12$1,357
Metronidazole24$981
Tacrolimus16$950
Clindamycin Phosphate26$868
Ketoconazole60$866
Triamcinolone Acetonide72$687
Dutasteride59$607
Minoxidil106$582
Doxycycline Hyclate29$419
Fluconazole37$383
Hydrocortisone59$341

Paid to pharmacies, not to this prescriber.

Other dermatology in Fayetteville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →